• Human APIs PowderRespiratory Drugs Raw Material Antiviral Antibacterial Antipyretic Analgesics Antihistamine Drugs Antineoplastic Cosmetic Raw Material
  • Pharmaceutical IntermediatesPharmaceutical intermediates Nutritional Supplements Pharmaceutical raw materials
  • OEM & ODMCapsule Softgel Capsule Gummies Drop & drinks Tables
  • Veterinary raw materialsAntibacterial anti-inflammatory Respiratory Drugs Anthelmintics Antiviral drugs Feed additives
  • About UsCompany profileQualificationQuality AssuranceService teamFactory TourR&D Center
  • Mifepristone Powder CAS 84371-65-3 Powder Raw Material

    • Mifepristone Powder CAS 84371-65-3 Powder Raw Material
    • Mifepristone Powder CAS 84371-65-3 Powder Raw Material
    • Mifepristone Powder CAS 84371-65-3 Powder Raw Material storehouse
    • Mifepristone Powder CAS 84371-65-3 Powder Raw Material quality testing
    • Mifepristone Powder CAS 84371-65-3 Powder Raw Material quality testing
    • Mifepristone Powder CAS 84371-65-3 Powder Raw Material certificate

    Product Overview:

    Mifepristone CAS 84371-65-3, molecular formula: C29H35NO2, Mifepristone Powder Raw Material is Yellow solid. Mifepristone Powder has strong anti-progesterone activity, Mifepristone is a novel antiprogestin with antiglucocorticoid activity. Clinically, it can be used for anti-early pregnancy, inducing menstruation, and contraception afterward.

    Mifepristone Powder CAS 84371-65-3 Powder Raw Material Attributes

    Product Name: Mifepristone Powder CAS 84371-65-3 Powder Raw Material

    CAS: 84371-65-3

    MF: C29H35NO2

    Mifepristone Powder

    Specification​: 99% min Mifepristone

    Sample:  Mifepristone Powder

    Brand: Henrikang

    Appearance: White Powder

    Storage: Cool Dry Place

    Shelf Life: 2 Years

    Test Method: HPLC

    Mifepristone Powder CAS 84371-65-3 Powder Raw Material Details

    Mifepristone Powder Usage and Synthesis:

    Mifepristone CAS 84371-65-3, molecular formula:  C29H35NO2, Mifepristone Powder Raw Material is Yellow solid. Mifepristone Powder has strong anti-progesterone activity,  Mifepristone is a novel antiprogestin with antiglucocorticoid activity. Clinically,  it can be used for anti-early pregnancy, inducing menstruation, and contraception afterward. Mifepristone, also known as antiprogesterone, Sibex, Siyin, containing chloridin, Simian, Minasterone, belongs to antiprogesterone drugs, is a new type of anti-fertility drugs acting on the level of receptors, without progesterone, androgen, estrogen activity. It mainly acts on the endometrioprogesterone receptor, which can bind to the progesterone receptor and glucocorticoid receptor, and has a high affinity. Its affinity for the endometrioprogesterone receptor is 5 times stronger than that of progesterone. At the effective dose, it has no significant effect on the cortisol level, and can produce strong anti-progesterone effect, resulting in degeneration of the deciduae and the vili tissues of pregnancy, and the release of endogenous prostaglandin. Lead to uterine contraction, at the same time can reduce the production of human chorionic gonadotropin, luteolysis, so that the embryo abortion.

    Mifepristone Powder

    Because the drug cannot cause enough uterine activity, the rate of incomplete abortion is high when it is used only for anti-early pregnancy, but it can increase the sensitivity of the uterus to prostaglandin. Therefore, adding a small dose of prostaglandin can not only reduce the adverse reaction of prostaglandin, but also significantly increase the rate of complete abortion. In addition, mifepristone also has the effect of softening and dilating the cervix. Clinical can be used for anti-early pregnancy, induce menstruation, after contraception, stillbirth induction and promote cervical maturity, can also be used for gynecological operations, such as the placement and removal of intrauterine device, endometrial specimen, cervical tube development abnormalities laser separation and cervical dilation and curettage.

    Pharmacokinetics of Mifepristone Powder:

    Mifepristone is a new type of anti-progesterone, and has the activity of anti-glucocorticoid, can be used for anti-early pregnancy, promote menstration and stop pregnancy, fetal death intrauterine induction of labor, and can also be used for gynecological surgery operations, such as the removal and placement of intrauterine device, removal of endometrial specimen, laser separation of cervical duct development abnormalities and cervical dilation and curettage.Pharmaceutical Raw Material Mifepristone can prevent implantation of fertilized eggs, induce menstruation, and promote cervical maturation. After clinical use, dizziness, nausea, vomiting, abdominal pain and other symptoms are easy to appear. The novel antiprogesterone has antiglucocorticoid activity, but no progesterone, estrogen, androgen and antiestrogen activity. And progesterone receptor affinity is 5 times stronger than progesterone. Used for anti-early pregnancy, menstruation stop pregnancy, fetal death official induction of labor, etc.

    Mifepristone CAS 84371-65-3

    Clinical Application of Mifepristone Powder:

    Mifepristone can terminate pregnancy, prevent implantation, induce menstruation, and promote cervical maturation.

    Mifepristone can also enhance the sensitivity of pregnant uterus to prostaglandin, can use small doses of mifepristone and prostaglandin drug sequential use, can achieve the effect of termination of early pregnancy.

    Mifepristone can also be used for emergency contraception, such as during unprotected sex or within 72 hours of contraceptive failure, and for the preoperative treatment of uterine fibroids with severe symptoms in women of childbearing age.

    Mifepristone is a receptor level antiprogesterone, which has the functions of terminating early pregnancy, anti-implantation, inducing menstruation and promoting cervical maturation. It competes with progesterone for receptor and achieves antagonistic effect of progesterone, and has certain binding force with glucocorticoid receptor. Mifepristone can significantly increase the sensitivity of pregnancy uterus to prostaglandin, low dose of mifepristone sequentially combined with prostaglandin drugs, can obtain satisfactory termination of early pregnancy effect.

    Mifepristone CAS 84371-65-3

    Mifepristone Powder Raw Materials can be made into drugs with the following properties:

    (1) Mifepristone capsules: hard capsules, the content is light yellow powder.

    (2) Mifepristone tablets: yellowish tablets.

    (3) Mifepristone soft capsules: the contents are light yellow clear liquid.

    The specifications are as follows:

    Mifepristone Capsules: 12.5mg. Mifepristone tablets:

    (1) 10mg;

    (2) 25mg;

    (3) 0.2g.

    Mifepristone Soft Capsules: 5mg.

    Pharmaceutical Raw Material

    Active Pharmaceutical Ingredients Raw Material

    Our advantage
    Our Factory
    Shipping
    Tel: 86-29-89601602
    WhatsApp: 8615091775531
    WeChat: 15091775531
    E-mail: sales21@interlgroup.com
    Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
    ©2023 Xi'an Henrikang Biotech Co., Ltd.,